Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases - Takeaways - MDSpire

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

  • By

  • Zhipeng Fan

  • Peikai Sun

  • Lei Li

  • July 6, 2026

  • 0 min

Share

  • 1

    The study analyzed adverse drug events (ADEs) associated with aromatase inhibitors and CDK4/6 inhibitors using FAERS and JADER databases.

  • 2

    A total of 28,495 reports related to combination therapy were included in FAERS, identifying 150 ADEs.

  • 3

    The most frequently reported ADEs included fatigue, neutropenia, and decreased white blood cell count.

  • 4

    Combination therapy showed stronger reporting signals for certain ADEs, including neutropenia and anemia, compared to monotherapy.

  • 5

    Multivariate logistic regression indicated that body weight was associated with serious outcomes and hematological toxicity.

Original Source(s)

Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases

  • by Zhipeng Fan, Peikai Sun, Lei Li

  • July 6, 2026

Related Content

Multimodal imaging features of primary breast epithelial–myoepithelial carcinoma: a case report and literature review

Breast Cancer Incidence in Asian American, Native Hawaiian, and Pacific Islander Populations, 2000-2022

Potential profile analysis of return-to-work readiness and self-efficacy in postoperative breast cancer patients who have returned to work